A Study of AL8326 in Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: AL8326 tablets
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 158
- Registration Number
- NCT06794957
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medicaal University, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Xuancheng People´s Hospital, Xuancheng, Anhui, China
Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
- Conditions
- Sarcoma,Soft TissueGynecologic Cancer
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Advenchen Laboratories, LLC
- Registration Number
- NCT05612191
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- Conditions
- Alveolar Soft Part SarcomaSynovial SarcomaSoft-Tissue SarcomaLeiomyosarcoma
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 325
- Registration Number
- NCT03016819
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
- Conditions
- Fallopian Tube CarcinomaCervical CarcinomaEndometrial CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 294
- Registration Number
- NCT02584478
- Locations
- 🇺🇸
The Oncology Institute of Hope and Innovation, Long Beach, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Baptist Health Lexington Oncology Research, Lexington, Kentucky, United States
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
- Conditions
- Endometrial CancerOvarian CancerCervical Cancer
- Interventions
- Drug: AL3818
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02558348
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States